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Background: The decreased number and senescence of circulating endothelial progenitor cells (EPCs) are
considered markers of vascular senescence associated with aging, atherosclerosis, and coronary artery disease (CAD)
in elderly. In this study, we explore the role of vascular senescence in premature CAD (PCAD) in a developing
country by comparing the numerical status and senescence of circulating EPCs in PCAD patients to controls.
Methods: EPCs were measured by flow cytometry in 57 patients with angiographically documented CAD, and 57
controls without evidence of CAD, recruited from random patients ≤ 50 years of age at All India Institute of Medical
Sciences. EPC senescence as determined by telomere length (EPC-TL) and telomerase activity (EPC-TA) was studied
by real time polymerase chain reaction (q PCR) and PCR– ELISA respectively.
Result: The number of EPCs (0.18% Vs. 0.039% of total WBCs, p < 0.0001), and EPC-TL (3.83 Vs. 5.10 kb/genome,
p = 0.009) were markedly lower in PCAD patients compared to controls. These differences persisted after adjustment
for age, sex, BMI, smoking and medications. EPC-TA was reduced in PCAD patients, but was statistically significant
only after adjustment for confounding factors (1.81 Vs. 2.20 IU/cell, unadjusted p = 0.057, adjusted p = 0.044).
Conclusions: We observed an association between increased vascular cell senescence with PCAD in a sample of
young patients from India. This suggests that early accelerated vascular cell senescence may play an important
mechanistic role in CAD epidemic in developing countries like India where PCAD burden is markedly higher
compared to developed countries.
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Telomerase activityBackground
While coronary vascular disease (CVD) and coronary ar-
tery disease (CAD) occurs predominantly among older
individuals in developed countries, it occurs at earlier
ages in developing countries. The proportion of CVD
deaths below 70 years of age in 1990 was only 22.8% in
the established market economies, whereas it was 52.2%
in India [1]. It is unclear why communities where CAD* Correspondence: rlakshmy@aiims.ac.in
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reproduction in any medium, provided the oris emerging as a threat have a high burden of premature
coronary artery diseases (PCAD) [2].
The development of CAD among elderly has been as-
sociated with the progression of senescence in almost all
cellular elements of the vascular system [3,4]. Endothe-
lial dysfunction is presumed to play a crucial role in the
development of atherosclerosis and coronary artery dis-
ease spectrum including PCAD [5]. Circulating endothe-
lial progenitor cells (EPCs) mobilized from the bone
marrow by the vascular system provide an endogenous re-
pair mechanism for endothelial cell injury [6], and may
therefore have an important role in the pathophysiologytral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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impairment of circulating EPCs has been associated with
aging and senescence of vascular system, and more pro-
nounced numerical and functional decline of EPCs have
been associated with CAD among elderly [3,7-9]. Reduced
telomere length is considered a marker of senescence in
various cells including those in vascular system. Reduced
telomere length in EPCs (EPC-TL) is also associated with
CAD among elderly [3,7-9]. In addition, increased EPC
senescence has been shown to be associated with higher
risk for cardiovascular events in individuals [10], and risk
factors and clinical conditions like diabetes and hyperten-
sion are known to have detrimental effect on numerical
and functional levels of EPCs in CAD patients [11-15].
Based on demonstration of extensive association of vascu-
lar cell senescence with atherosclerosis and CAD, and evi-
dence of shared biochemical pathways between vascular
aging and atherosclerosis, others have suggested that
CAD among elderly can be viewed as accelerated aging
[4,16]. However, the role of accelerated vascular aging in
the pathogenesis of PCAD has not been explored before
in detail especially in the setting of a developing country
like India where the burden of PCAD is very high. In this
study we explore the role of numerical and functional de-
cline of EPCs, and telomere shortening of EPCs, markers
of vascular senescence in PCAD patients from India.
Methods
Subjects
The Ethics Committee of the All India Institute of Med-
ical Sciences (New Delhi, India), approved the protocol
and written informed consent was obtained from all
subjects prior to the study. A total of 57 subjects, age
≤ 50 years of either sex, with evidence of CAD as con-
firmed by the presence of either > 50% stenosis in the left
main coronary artery or > 70% stenosis in other arteries
on coronary angiography were recruited for the study
group. Fifty-seven age matched (± 5 years) non-diabetic
subjects of both genders without known heart disease
and either having a normal coronary angiogram or with-
out demonstrable ischemia on stress testing were re-
cruited as controls from random patients visiting
Cardiology department of All India Institute of Medical
Sciences (AIIMS), New Delhi, India from 2008 to 2010.
Subjects with any form of cancer, renal disease, rheuma-
toid arthritis, pneumonia, nephropathy and cerebrovas-
cular disease were excluded. 30 ml fasting venous blood
sample was collected in EDTA tubes. 200 μl of the whole
blood was used for EPC enumeration. Plasma was sepa-
rated from 3 ml of blood for biochemical analysis. Rest
of the blood was used for EPC isolation for measure-
ment of telomere length and telomerase activity. Insulin,
hsCRP (high sensitive C-reactive protein), and homo-
cysteine were analyzed by ELISA using kits fromMercodia (Sweden), Biochek (CA) and Diazyme (CA) re-
spectively. Glucose was measured by glucose oxidase,
total cholesterol by CHOD-PAP, and triglycerides by
GPO-PAP methods using kits from RANDOX (Crumlin,
UK). High density lipoprotein (HDL) cholesterol was
measured by precipitation method using RANDOX kits.
Insulin resistance was calculated using Homeostatic
Model assessment (HOMA). Low Density Lipoprotein
(LDL) was calculated using friedwald’s formula.
EPC enumeration
EPCs were quantified in blood by flow cytometry. Briefly
200 μl of peripheral blood was treated with FcR blocking
reagent (MiltenyiBiotec, Germany) and incubated with
Fluorescein isothiocyanate (FITC) labeled CD34 (BD Bio-
sciences, USA) and R-phycoerythrin (PE) labeled VEGFR2
antibodies (R&D systems, USA). Labeled cells were lysed
with Fluorescence-activated cell sorting (FACS) lysis buf-
fer (BD Biosciences, USA) and fixed. Baseline parameters,
compensation settings and gates were set using unstained
controls and isotype controls. EPCs were identified as
CD34+/KDR + dual positive cells in the upper right quad-
rant region. A total of 500,000 events were recorded in
each unstained and stained sample. The numbers of
CD34+/KDR + cells were expressed as a percentage of
total WBC.
EPC isolation
Mononuclear cells (MNC) were isolated from blood
samples by HISTOPAQUE®-1077 (Sigma chemicals,
India) density gradient centrifugation according to man-
ufacturer’s protocol. EPCs were isolated using a two step
protocol of Magnetic Activated Cell Sorting (MACS)
using CD 34 multisort kit (MiltenyiBiotec, Germany)
and indirect labeling procedure with PE labeled VEGFR2
(R&D systems, India) and anti-PE micro beads (Miltenyi
Biotec, Germany). Briefly, MNC were treated with FcR
blocking reagent (Miltenyi Biotec, Germany) and incu-
bated with CD34 multisort beads and PE labeled VEGFR2.
The CD34 labeled cells were separated through positive
selection and incubated with anti-PE microbeads and cells
which were dual positive for CD34/VEGFR2 collected,
counted and aliquoted for telomere length and telomerase
activity assays.
Measurement of EPC Telomere length (EPC-TL)
EPC-TL was measured by real time PCR method as de-
scribed by Cawthon et al. [17] Callaghan et al. [18] and
N Callaghan and Fenech [19] with minor modifications.
Measurement of EPC Telomerase activity (EPC-TA)
EPC Telomerase activity (EPC-TA) was measured by a
combination of telomeric repeat amplification protocol






Age (yrs) 43.1 ± 6.36 39.8 ± 6.13 0.125
Height (cm) 165.8 ± 5.63 168.9 ± 6.99 0.008
Weight (kg) 69.1 ± 11.25 69.2 ± 12.30 0.959
BMI (kg/m2) 24.8 ± 3.96 24.2 ± 3.91 0.472
Family history for CAD (n) (%) 18 (31.6) 6 (10.5) 0.006
Family history for
hypertension (n) (%N)
2 (3.5) 6 (10.5) 0.142
SBP (mmHg) 127.9 ± 11.88 127.46 ± 14.87 0.855
DBP (mmHg) 83.4 ± 6.82 81.8 ± 8.95 0.290
Statins, n (%) 36 (63.0) 7 (12.0) <0.001
ACE – Inhibitors, n (%) 21 (37.0) 6 (10.5) <0.001
ß – blockers, n (%) 28 (49.0) 2 (3.5) <0.001
Aspirin, n (%) 41 (72.0) 10 (17.5) <0.001
PPAR-γ agonists n (%) 1 (2.0) 0 (0.0) 0.229
LVEF% (mean ± SD) 44.6 ± 1.77 60.40 ± 1.56 0.001
Diabetes n (%) 9 (15.8) –
Hypertension, n (%) 13 (22.8) 14 (24.6) 0.785
Smoking, n (%) 24 (42.1) 14 (24.6) 0.047
Alcohol, n (%) 11 (19.3) 16 (28.1) 0.083
Table 2 Biochemical characteristics of subjects
PCAD Controls P value
Means ± SD Means ± SD
(N = 57) (N = 57)
Total cholesterol (mg/dl) 128.5 ± 32.7 171.1 ± 36.0 <0.001
Triglycerides (mg/dl) 112.6 ± 59.2 175.5 ± 108.5 <0.001
HDL (mg/dl) 35.3 ± 7.1 40.8 ± 5.5 <0.001
VLDL (mg/dl) 22.7 ± 11.9 34.4 ± 20.0 <0.001
LDL (mg/dl) 72.7 ± 30.5 96.2 ± 25.3 <0.001
LDL/HDL ratio 2.13 ± 0.96 2.4 ± 0.84 0.076
Glucose (mg/dl) 100.3 ± 44.3 96.4 ± 15.5 0.477
Insulin (mU/L) 8.9 ± 6.1 11.5 ± 10.7 0.074
Insulin resistance 2.31 ± 2.0 2.89 ± 3.2 0.199
CRP (mg/dl) 3.01 ± 3.4 3.5 ± 3.03 0.316
Homocysteine (μmol/L) 18.23 ± 11.99 13.65 ± 9.90 0.038
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to manufacturers protocol (Roche Diagnostics, India).
Statistical methods
Statistical analysis was performed using STATA statis-
tical software (version 9.0 for windows). Fifty patients
and 50 controls were needed for 90% power and α of
0.05. We elected to recruit additional subjects within a
stipulated time and a ceiling of 60. Normality of the
sampling distribution of each variable was tested using
Kolmogorov-Smirnov test for normality. The distribu-
tions of EPC number, EPC-TL, and EPC-TA were not
normal and therefore log transformed for analysis. Con-
tinuous variables like age, height, weight, BMI, systolic
blood pressure, diastolic blood pressure, medication
dose, left ventricular ejection fraction (LVEF)% and bio-
chemical estimates were expressed as Mean ± SD (Stand-
ard Deviation) and categorical variables were expressed
as numbers and percentage. Log transformed variables
were expressed as geometric mean with 95% confidence
intervals (95% CI). Baseline characteristics and bio-
chemical estimates of cases and controls were compared
using unpaired student’s t test. Categorical variables that
were not normally distributed were analyzed using
Wilcoxon rank sum test. Student’s t test was used to
compare the means of EPC number, EPC-TL, and EPC-
TA in cases and controls. Linear regression analysis was
employed to adjust for confounding variables. Bivariate
and partial correlations were computed for assessing
correlations between EPC number/EPC senescence and
biochemical parameters. Confounding variables taken for
adjustment included age, sex, BMI, smoking and medica-
tions. Statistical significance was assumed if P value was
less than or equal to 0.05.
Results
The baseline characteristics are detailed in Tables 1 and 2.
The proportion of female patients were low in both PCAD
(1) or control group (4), and family history of CAD was
more often present in PCAD group. Use of statins, ACE-
inhibitors, β blockers and aspirin was significantly higher
in PCAD. PCAD group had lower mean total cholesterol,
LDL, HDL and triglycerides, possibly reflecting higher sta-
tin use, but had significantly higher homocysteine levels
compared to controls.
Circulating EPC number and senescence
Figure 1A and 1B shows the flow cytometry analysis of
circulating EPCs. Figure 1B shows the stained EPCs. As
shown in Table 3 the mean percent of EPCs were signifi-
cantly lower in PCAD patients compared to controls,
and this persisted after adjustment for confounding vari-
ables. The mean EPC-TL was also markedly lower in
PCAD patients compared to controls and the differenceremained significant after adjustment. The mean relative
EPC-TA was lower in PCAD patients as compared to
controls, but the difference was statistically significant
(P = 0.044) only after adjusting for confounding vari-
ables. Additionally adjusting for family history of dia-
betes did not change these associations. The EPC
numbers were lower in smokers as compared to non
smokers (0.022% vs. 0.014%) but the difference was not
statistically significant (p = 0.127).
Figure 1 Unstained (A) and stained (B) quadrangle plot of CD34-Fluorescence isothiocyanate in forward scatter and versus VEGRF2
(KDR)-phycoerythrin in the side scatter in one representative patient sample. The upper right quadrant shows the dual stained EPCs.
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EPC levels and EPC senescence
In controls, EPC number positively correlated with total
cholesterol before and after adjusting for age, sex, BMI
and smoking (Unadjusted Pearson r = 0.231, P = 0.021,
Adjusted Pearson r = 0.218, P = 0.033). However theassociation was lost when adjusted for medications. HDL
levels were positively correlated with EPC number (Un-
adjusted Pearson r = 0.284, P = 0.004, adjusted r = 0.241,
P = 0.018). In PCAD patients EPC numbers negatively
correlated with triglyceride levels (unadjusted Pearson
r = −0.280, p = 0.049 and adjusted Pearson r = −0.380,
Table 3 Number and senescence of circulating endothelial progenitor cells in premature CAD patients compared to
normal controls
Parameter PCAD patients Controls P value Adjusted P value*
EPC number (% of total WBC) 0.018 (0.013-0.023) 0.039 (0.031-0.043) <0.001 0.001
EPC telomere length (kb/genome) 3.83 (3.20-4.50) 5.10 (4.26-6.10) 0.009 0.050
EPC telomerase activity (IU/cell) 1.81 (1.30-2.40) 2.20 (1.50-3.20) 0.057 0.044
*Adjusted for age, sex, BMI, smoking and medication.
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(Unadjusted Pearson r = −0.326, P = 0.014 and adjusted
r = −0.289, P = 0.038). EPC-TL positively correlated with
EPC-TA (Pearson r = 0.409, P = 0.002).
Discussion
We observed markedly lower numbers of circulating
EPCs in young patients with angiographically docu-
mented CAD from India as compared to controls with-
out CAD. In addition, the EPCs from PCAD patients
also showed a marked decrease in telomere length and
telomerase activity. The difference remained even after
adjusting for all the confounding variables (age, sex,
BMI, use of medication and smoking). Our findings sug-
gest that PCAD patients in India have accelerated vascu-
lar senescence compared to those without CAD. EPC
number and telomere length also negatively correlated
with serum triglyceride levels in patients.
The results reported in the present study are in agree-
ment with other studies reporting a reduced EPC num-
ber in older CAD patients. Vasa et al. [20] reported
lower EPC (CD34/KDR positive) numbers and function
in CAD patients with a mean age of 62 years. Eizawa
et al. has also reported a similar reduction in EPC
(CD34+ cells) number in CAD patients [21]. Aging asso-
ciated numerical and functional decline in EPCs in CAD
patients has been attributed to exhaustion of stem/pro-
genitor cells in the bone marrow due to chronic vascular
injury, reduced mobilization, diminished migratory and
adhesion capacity of EPCs and deregulation of EPC dif-
ferentiation [22,23], and is thought to render the elderly
more prone to endothelial dysfunction and cardiovascu-
lar disease [24]. Results of our study suggest that low
EPC levels may be responsible for endothelial dysfunc-
tion and atherosclerosis in PCAD patients as well.
A shorter EPC-TL in PCAD patients reported in the
present study points towards accelerated senescence of
EPCs resulting in lower EPC number, suggestive of com-
promised repair of dysfunctional endothelium. EPC telo-
mere shortening and decreased EPC telomerase activity
has been reported in older patients with stable and un-
stable CAD [25,26]. Kushner et al. reported age related
decline of EPC-TL in healthy men from a developed na-
tion, starting after the age of 55 years, and EPC-TL was
20% shorter in older as compared to middle aged menand young suggesting EPC telomere shortening may be
responsible for age related endothelial dysfunction [23].
In our study, the PCAD patients with a mean age of
43 years show a similar decline in TL (25% reduction)
compared to controls of similar age, suggesting an earl-
ier onset of EPC senescence in them. Increased oxidative
stress associated with metabolic derangements has been
suggested as an explanation for the shorter EPC telo-
meres and EPC lower telomerase activity [25], and this
could be applicable to younger patients too. We did not
measure markers of oxidative stress in our study. The
negative correlation between triglycerides and EPC num-
ber and senescence on our study would be relevant as
Indians are known to consume high carbohydrate diet,
and have higher triglyceride levels. The PCAD patients
showed lower triglyceride levels possibly due to statin
use [26]. Other authors have also reported an association
between EPC and triglycerides [27]. Triglyceride rich li-
poproteins have been shown to increase senescence of
endothelial progenitor cells via oxidative stress [28].
Since the subjects in this study had a mean age of 43,
age is unlikely to be the culprit for low EPC count and
higher level of EPC senescence in PCAD patients. This
EPC senescence is probably driven by multiple factors
including increased oxidative stress due to smoking, and
atherogenic lipoprotein phenotype characterized by high
triglycerides and low HDL.
Recent studies have shown that diet may have signifi-
cant influence on EPC-TL and EPC-TA [29]. As with
cardiac risk factors, non-pharmacologic intervention like
exercise [30,31], and diet modification [29,32] can posi-
tively influence vascular aging along with medications
like statins [33]. Statins are known to promote EPC
mobilization, proliferation, migration, adhesion, and dif-
ferentiation, and reduce senescence. We did not find any
significant correlation between dose of statins and EPC
number and EPC senescence in our study possibly be-
cause most of our subjects were on low dose of statins.
Though prematurely speculative, this study with the
context of prior evidence from developed countries pro-
vides interesting insights into the mechanisms of prema-
ture CVD in Indians. Autopsy studies from United
States have shown that coronary atherosclerosis have
markedly declined from 77% prevalence in 1950s to
8.5% in 2011, a period of sharp decline in premature
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[34], suggesting that the high CAD burden among mid-
dle aged adults in 1940s and 1950s in United States (as
seen now in countries like India and China) was prob-
ably driven by “reservoir” of atherosclerosis in the young
population, and the abundance of noxious risk factors
[35]. Aging associated atherosclerosis can be considered
as accelerated vascular aging probably influenced by
additional pathological burden induced by various other
noxious environments like smoking, dyslipidemia, and
hypertension [16], and atherosclerosis occurring at
younger age could be due to early accelerated aging of
the vascular wall [4]. Consistent with this view, our data
suggests that senescence of vascular system may be hap-
pening early in an accelerated fashion in PCAD patients
from developing countries. Nilsson et al. has suggested
that the early vascular aging including telomere anomal-
ies that lead to atherosclerosis is probably a reflection of
more generalized early biological aging in susceptible in-
dividuals, and this susceptibility is partly driven stresses
of early life like fetal health and early childhood adverse
growth patterns [36], a situation still common in coun-
tries like India. Putting all of this together, it is tempting
to speculate that as survival rates at young ages in devel-
oping countries increase and the high exposure to fetal
and early life stresses persist, the “reservoir” of suscep-
tible people with early vascular aging (and general bio-
logical aging) in developing country like India can be
very high. The exponentially increasing prevalence of
atherogenic risk factors at young adulthood in developing
countries [37] may be further accelerating the vascular
senescence in the population, especially among the already
susceptible ones. This complex interplay between early-
accelerated vascular senescence biology and the environ-
mental factors like urbanization, nutrition, and ecology of
living environments is probably a crucial driver of the epi-
demic of premature CAD in developing countries.
We have not excluded patients who are on statin ther-
apy, which influence EPC number. We have however ad-
justed for the effect of statins and other medications in
statistical analysis. Further, we have not looked at the
functional and mobilization capacity of EPCs in prema-
ture CAD patients, possibly of greater importance than
absolute EPC number and needs to be addressed in fu-
ture studies. Unlike many prior studies EPC-TL and
EPC-TA in our study was measured directly in EPC iso-
lated from individuals, and not from EPC cultures, and
this more realistically mimic in-vivo conditions. More-
over the specific role of EPCs in development of athero-
sclerosis and CAD is still being clarified.
Conclusion
Significantly lower EPCs in premature CAD patients in
the present study suggest impaired repair mechanismpredisposing to endothelial dysfunction at younger ages.
Association of EPC senescence with triglycerides, which
is part of the atherogenic South Asian phenotype, is sug-
gestive of a possible role of classical risk factors in regu-
lating EPC number in this population. A shorter EPC
telomere length and a reduced telomerase activity, in the
young CAD patients in the present study, points to an
accelerated senescence of EPCs in vivo, resulting in
lower circulating EPCs. Together with prior data, our
study suggests that early-accelerated vascular senescence
may be a crucial driver of premature CAD in developing
countries. The study also suggests that EPC telomere
length could be used as an early marker for detecting
impaired repair mechanism predisposing to endothelial
dysfunction in premature CAD patients. The pliability of
vascular aging to control of risk factors, and the possible
involvement of early life factors in the generation of
early accelerated vascular senescence/aging suggests that
national policies focusing simultaneously on early life
enhancement and chronic risk factor reduction maybe
likely to curtail the burden of premature CAD in devel-
oping countries.
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